Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Stopped Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects previously treated with a CAR T-cell product.
Conditions
- Non Hodgkin Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
Interventions
- GENETIC: JCAR017
- GENETIC: JCARH125
Sponsor
Juno Therapeutics, a Subsidiary of Celgene